Testimonials

In this interview, we spoke with Dr. Joanna Pucilowska, Senior Director of Immune Monitoring and Cancer Omics Labs at Oregon Health & Science University, about how COMET™ is helping her team accelerate panel development, streamline workflows, and scale spatial analysis. Developing and running a 20–25 marker panel with traditional chromogenic staining could historically take 4–6 weeks. With COMET™, her team now completes the same work in under two weeks, moving from experiment to insight significantly faster. Beyond the technology, she points to the COMET community as a key part of the experience: fast access to support, feedback, and shared knowledge from other users made onboarding and scaling the platform far smoother. 

Key benefits for core facilities:

• Faster time-to-results
• Hands-free, standardized workflows
• High-throughput
• Same-day iteration
• Responsive user community and support

COMET™ workflows are helping research teams scale spatial analysis and generate data that can contribute to patient care in days, not weeks. Watch full interview here. 

In this interview, we spoke with Dr. Zoe Butti, Postdoctoral Researcher at the New York Genome Center, to explore how COMET™ is giving her team the flexibility to build and adapt high-plex panels to answer evolving biological questions. Specializing in spatial transcriptomics, Zoe’s team needed a faster and more scalable way to validate transcriptomic findings at the protein level.  

The COMET™ platform enables Zoe’s team to:

• Scale to high-plex protein staining and imaging
• Validate spatial transcriptomic findings at the protein level
• Use standard, off-the-shelf antibodies without the need for conjugation
• Build and adapt panels as new biological questions emerge
• Generate more insights per tissue section

Watch Dr. Butti share how COMET™ is giving her team the flexibility and scalability to answer more complex biological questions. 

In this interview, we spoke with Dr. Leeat Keren, Principal Investigator at the Weizmann Institute of Science, to learn how her lab is using COMET™ to visualize the tumor microenvironment (TME). One capability changed her lab’s workflow more than any other: the ability to run standard, off-the-shelf primary antibodies on COMET™. This flexibility opened the door to a much broader antibody portfolio, including clones already widely used and clinically established, significantly expanding the range of markers her lab could explore while cutting prep time. 

The COMET™ Suite enables Dr. Keren’s lab to:

• Analyze 70+ proteins on a single tissue section
• Use standard, off-the-shelf non-conjugated antibodies
• Combine protein and RNA in the same panel
• Investigate the TME across diverse cancer types 

Watch the full interview to hear how COMET™ is helping her lab see the tumor ecosystem in ways that weren’t possible before.  

In this Meet-the-Expert Feature, we spoke with Patrick Reese, VP of Operations at CellCarta to learn more about how his team is leveraging COMET™ to advance spatial biology in biomarker development delivering consistent and high-quality data for global biopharma studies.

The COMET™ Suite enables CellCarta to:

• Standardize workflows across global laboratories
• Accelerate assay development and throughput
• Extract more insights from precious clinical samples
• Support multi-regional trials with harmonized data

CellCarta delivers a scalable, clinical-ready approach for biopharma, strengthening its position as a trusted partner for global clinical studies.

Learn more about COMET™ services offered by CellCarta.

Propath, a leading provider of molecular pathology and spatial biology services, adopted COMET™ to meet the growing demand for deeper biological insight from increasingly limited clinical trial samples. In this interview, Kelly Hunter, Chief Scientific Officer at Propath, explains how COMET™ fills the critical needs of delivering highly customizable, high‑plex panels without compromising quality, scalability, or turnaround time.

Fully-automated imaging and staining as well as seamless integration into Propath’s bioinformatics pipelines, accelerate multiplex assay development while ensuring consistent performance across long‑running, GCP‑compliant clinical programs. COMET’s gentle workflow preserves tissue integrity, enabling Propath to combine spatial proteomics and transcriptomics on the same precious tissue sections.

Biopharma and CRO partners rely on Propath’s COMET™‑enabled services to explore therapeutic mechanisms, understand cellular interactions, and uncover markers of response or resistance, all while maximizing insight from minimal tissue.

Key benefits for Propath and their clients:

• High throughput for rapid panel development and staining
• True multiomics with protein and RNA on the same slide
• Full flexibility to build custom or hybrid antibody panels
• Reproducibility at scale, even across multiple instruments

Learn more about Propath’s COMET™ services here.

Dr. Akil Merchant, physician and researcher at Cedars-Sinai, is advancing cancer research in the tumor microenvironment by integrating immuno-metabolic profiling at scale. His team designed an 82-marker immuno-metabolic panel using the COMET™ platform, bringing together markers of immune function, metabolism, and cellular signaling in one assay.

In this interview, Dr. Merchant dives into:

• How his lab’s approach balances depth and throughput;
• The role of full automation in ensuring consistent, reproducible results;
• Why COMET™ is uniquely suited for translational biomarker research.

Watch the full video to hear Dr. Merchant’s perspective on hyperplex spatial biology and its future impact on personalized cancer therapy.

We had the opportunity to speak with Dr. Hinda Najem, a Postdoctoral Research Fellow in the Department of Neurological Surgery at Northwestern University, about how the COMET™ platform has transformed her research. Dr. Najem dedicates her work to exploring spatial proteomics techniques to better understand primary and metastatic cancers of the central nervous system and complex brain diseases. She emphasizes the critical role that cutting-edge tissue profiling technologies, like COMET™, play in advancing  translational research and achieving impactful results. 

Watch the video to discover: 

• How Dr. Najem leverages COMET™ to enable rapid optimization of new antibodies, making it indispensable for time-sensitive projects; 

• Why COMET™’s hyperplexing capabilities have been a game-changer in expanding her research possibilities; 

• Why the platform stands out as the ideal choice for advancing translational research goals. 

With so many technologies to study spatial proteomics available on the market, it is hard to choose the best one for your needs. Listen to our exclusive interview with Dr. Andrew Filer, Head of the Birmingham Tissue Analytics Facility at the University of Birmingham, in which he explains why COMET™ is their go-to platform.

Play the video and discover:

• For what purpose, Dr. Andrew Filer recommends COMET™ to other core facilities, researchers, and clinicians.
• How COMET™ complements other technologies installed at the core facility in Birmingham.
• How COMET™ integrates into their core facility workflow.

• Why is multiplex immunofluorescence crucial to study viral infections and their effects on host cells?
• Why he would recommend COMET™ to other pathologists?
• What advice he would give to people getting into automated staining and imaging technology?